

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from July 2016

For further details see *PACE Bulletin* Volume 10; Number 13 (August 2016)

SUMMARY OF PACEF DECISIONS: JULY 2016 UPDATE

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Brivaracetam 10mg, 25mg, 50mg, 75mg and 100mg tablets and 10mg/ml oral solution (<i>Briviact</i>) (UCB)	For use as an adjunct in partial-onset seizures with or without secondary generalisation.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Individual Funding Requests will be considered in exceptional cases.
Diltiazem 60mg modified release tablets (<i>Retalzem</i>) (Kent Pharmaceuticals)	Prophylaxis and treatment of angina pectoris	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . All prescriptions for diltiazem 60mg modified release tablets should specify the lower cost <i>Tildiem</i> brand.
Diltiazem 60mg modified release tablets (<i>Tildiem</i>) (Sanofi-Aventis)	Prophylaxis and treatment of angina pectoris	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . All prescriptions for diltiazem 60mg modified release tablets should specify the lower cost <i>Tildiem</i> brand.
Diltiazem 120mg, 180mg, 240mg, 300mg and 360mg SR capsules (<i>Viazem XL</i>) (Genus)	For angina and mild to moderate hypertension	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . Where a once daily SR diltiazem preparation is indicated either <i>Viazem XL</i> or <i>Zemtard</i> should be preferred. All prescribing should be brand specific.
Diltiazem 120mg, 180mg, 240mg and 300mg SR capsules (<i>Zemtard XL</i>) (Galen)	For angina and mild to moderate hypertension	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . Where a once daily SR diltiazem preparation is indicated either <i>Viazem XL</i> or <i>Zemtard XL</i> should be preferred. All prescribing should be brand specific.
Doxycycline 40mg modified release capsules (MR) (<i>Efracea</i>) (Galderma)	For the treatment of facial rosacea.	RED-RED. Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Levetiracetam tablets 250mg, 500mg, 750mg, 1g and oral solution 100mg/ml (generic)	For monotherapy in partial seizures with or without secondary generalisation in patients with newly diagnosed epilepsy. Adjunct in partial seizures with or without secondary generalisation. Adjunct in juvenile myoclonic epilepsy. Adjunct in idiopathic generalised epilepsy.	AMBER without shared care. Included in the <i>Lincolnshire Joint Formulary</i> .
Naproxen effervescent tablets 250mg (Stirlescent) (Stirling Health)	For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, acute	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Ibuprofen oral suspension

	musculoskeletal disorders and dysmenorrhoea.	100mg in 5ml is available on the <i>Lincolnshire Joint Formulary</i> and presents a preferred alternative at an equivalent cost.
Naproxen 125mg in 5ml oral suspension (Tariff special)	Unlicensed	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Ibuprofen oral suspension 100mg in 5ml is available on the <i>Lincolnshire Joint Formulary</i> and presents a preferred alternative at a much lower cost.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

What's new this month?

- **The MHRA has started a review of canagliflozin after an increase in amputations, mostly toes, was observed in an ongoing clinical trial called CANVAS. At this stage in the trial, there are cases of lower limb amputation in both the canagliflozin and the placebo groups, although the incidence is higher in the canagliflozin groups. No increase in such amputations has been seen in 12 other completed canagliflozin trials. Healthcare professionals should ensure that diabetic patients are aware of the importance of routine footcare to avoid cuts or sores of the feet and to treat them promptly should they occur to prevent infection and ulceration. Patients at increased risk of amputation (such as those who have already had a previous amputation) should be carefully monitored. Doctors should consider stopping canagliflozin in patients who develop significant foot problems (see page 10 of the bulletin).**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION